Abstract:Umbilical cord blood (UCB) has gained recognition as a viable alternative to bone marrow or mobilized peripheral blood for hematopoietic stem cell transplantation and is being used for treatment of mainly pediatric patients with various malignant or genetic blood disorders. The limited number of cells contained in a single cord blood unit remains the major bottleneck for broader application of this treatment in adult patients. Extensive research is being focused on strategies for overcoming this bottleneck. Expansion of cells from a single cord blood unit or combining 2 cord blood units for a single transplantation are the 2 most common strategies currently in clinical evaluation.Our research effort is focused on the expansion of umbilical cord blood cells. At BD Technologies, we have developed a unique higher-throughput technology platform that we have used successfully to identify a serum-free in vitro culture condition that supports expansion of UCB-derived cells. Expansion of UCB cells in this condition results in a unique cell population, characterized by a high level of glycoprotein CD34 expression. Characterization of this expanded population using flow cytometry, colony-forming assays, and gene array analysis indicate that this expanded cell population contains more primitive stem/progenitor cells than the remainder of the CD34+ population after expansion. When transplanted into sublethally irradiated NOD/SCID mice, these cells were found to engraft in the bone marrow and to develop CD19+ B-cell, CD33+ myeloid, CD34+ stem and progenitor, CD14+ monocyte, and CD42+ megakaryocyte lineages. Secondary transplantation studies indicate the long-term engraftment potential of the expanded cells.In addition, when transplanted subcutaneously on porous polymer carriers into NOD/SCID mice, the expanded cord blood cells are found to initiate neovascularization within the carrier. Immunohistochemistry revealed that human cord blood cells were incorporated into the new vasculature. We conclude that our culture condition supports expansion of UCB cells that may have relevance for therapeutic applications in humans. Umbilical cord blood (UCB) has gained recognition as a viable alternative to bone marrow or mobilized peripheral blood for hematopoietic stem cell transplantation and is being used for treatment of mainly pediatric patients with various malignant or genetic blood disorders. The limited number of cells contained in a single cord blood unit remains the major bottleneck for broader application of this treatment in adult patients. Extensive research is being focused on strategies for overcoming this bottleneck. Expansion of cells from a single cord blood unit or combining 2 cord blood units for a single transplantation are the 2 most common strategies currently in clinical evaluation. Our research effort is focused on the expansion of umbilical cord blood cells. At BD Technologies, we have developed a unique higher-throughput technology platform that we have used successfully to identify a serum-free in vitro culture condition that supports expansion of UCB-derived cells. Expansion of UCB cells in this condition results in a unique cell population, characterized by a high level of glycoprotein CD34 expression. Characterization of this expanded population using flow cytometry, colony-forming assays, and gene array analysis indicate that this expanded cell population contains more primitive stem/progenitor cells than the remainder of the CD34+ population after expansion. When transplanted into sublethally irradiated NOD/SCID mice, these cells were found to engraft in the bone marrow and to develop CD19+ B-cell, CD33+ myeloid, CD34+ stem and progenitor, CD14+ monocyte, and CD42+ megakaryocyte lineages. Secondary transplantation studies indicate the long-term engraftment potential of the expanded cells. In addition, when transplanted subcutaneously on porous polymer carriers into NOD/SCID mice, the expanded cord blood cells are found to initiate neovascularization within the carrier. Immunohistochemistry revealed that human cord blood cells were incorporated into the new vasculature. We conclude that our culture condition supports expansion of UCB cells that may have relevance for therapeutic applications in humans.

Increasing the Efficacy of Umbilical Cord Blood Banking Using Machine Learning Algorithms: A Case Study from Royan Cord Blood Bank

BUPNN: Manifold Learning Regularizer-Based Blood Usage Prediction Neural Network for Blood Centers

Predictors of cord blood unit cell content in a volume unrestricted large series collections: a chance for a fast and cheap multiparameter selection model

Development of a quantitative prediction algorithm for human cord blood-derived CD34+ hematopoietic stem-progenitor cells using parametric and non-parametric machine learning models

Survival Prediction of Children after Bone Marrow Transplant Using Machine Learning Algorithms

Evaluation of the Efficacy and Safety of Treatment on Using Single-Unit Unrelated Umbilical Cord Blood Transplantation Based on Umbilical Cord Blood Provided by China's Public Cord Blood Bank

Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC)

Influence of maternal, infant, and collection characteristics on high-quality cord blood units in Guangzhou Cord Blood Bank

Machine Learning Prediction Model for Neutrophil Recovery after Unrelated Cord Blood Transplantation

Abstract 6: Value of a Multi-Regional Cord Blood Bank Program: Multiple Collection Centers to Select High-Quality Units for Transplantation

In Vitro Umbilical Cord Blood Expansion Resulting in Unique CD34Bright Cell Population That Engrafts in NOD/SCID Mice

Abstract 20: National Cord Blood Network Training Tool to Optimize Cord Blood Unit (CBU) Selection

BCNet: A Deep Learning Computer-Aided Diagnosis Framework for Human Peripheral Blood Cell Identification

Umbilical Cord Blood Transplantation: Still Growing and Improving

Refining Eligibility Criteria of Unit Selection for Myeloablative Cord Blood Transplantation in Acute Leukemia: Real-world Experience of a Referral Center

Evaluation of clinical efficacy of single-unit unrelated umbilical cord blood transplantation based on umbilical cord blood provided by China's public cord blood bank

Prediction of Intraoperative Red Blood Cell Transfusion in Valve Replacement Surgery: Machine Learning Algorithm Development Based on Non-Anemic Cohort

A strategy of splitting individual high volume cord blood units into two half subunits prior to processing increases the recovery of cells and facilitates ex vivo expansion of the infused haematopoietic progenitor cells in adults

Allogeneic Umbilical Cord Blood Red Cell Concentrates: An Innovative Blood Product for Transfusion Therapy of Preterm Infants

Development of a machine learning approach for prediction of red blood cell transfusion in patients undergoing Cesarean section at a single institution

The utility of machine learning for predicting donor discard in abdominal transplantation